You are here

Health - US

Primary tabs

This working group is focused on discussions about health.

The mission of this working group is to focus on discussions about health.

Members

Corey Watts John Girard jonber37 Kathy Gilbeaux Lisa Stelly Thomas Maeryn Obley
mdmcdonald MDMcDonald_me_com mike kraft

Email address for group

health-us@m.resiliencesystem.org

WHO advises male Ebola survivors to abstain from sex

REUTERS                                                                                                                      NOV. 28, 2014

LONDON --Men who recover from Ebola should abstain from sex for three months to minimize the risk of passing the virus on in their semen, the World Health Organization (WHO) said on Friday.

Ebola, a disease that has infected and killing thousands in a vast epidemic in West Africa, normally spreads via bodily fluids such as blood, saliva and faeces. Although sexual transmission of Ebola virus disease has never been documented, the virus has been detected in the survivors' semen.

"Men who have recovered from Ebola virus disease should be aware that seminal fluid may be infectious for as long as three months after onset of symptoms," the WHO said in a statement....

Read complete story
http://www.reuters.com/article/2014/11/28/us-health-ebola-sex-idUSKCN0JC0UP20141128

Country / Region Tags: 
General Topic Tags: 
Problem, Solution, SitRep, or ?: 

Scientists: 'Positive' results in 1st human trial of experimental Ebola vaccine

CNN -- By Laura Smith-Spark                              Nov. 27, 2014

The first human trial of an experimental Ebola vaccine has produced promising results, U.S. scientists said, raising hopes that protection from the deadly disease may be on the horizon.

All 20 healthy adults who received the vaccine in a trial run by researchers from the National Institutes of Health in Maryland produced an immune response and developed anti-Ebola antibodies, the NIH said Wednesday.

None suffered serious side effects, although two people developed a brief fever within a day of vaccination.

The vaccine is being developed by the NIH's National Institute of Allergy and Infectious Diseases and British pharmaceutical giant GlaxoSmithKline. The process has been fast-tracked in light of the current catastrophic Ebola outbreak in West Africa, which has claimed more than 5,000 lives.

http://www.cnn.com/2014/11/27/health/ebola-outbreak/

General Topic Tags: 
Problem, Solution, SitRep, or ?: 

Sierra Leone Seeks U.S. Military Help to Fight Ebola

         

Health workers spray themselves with chlorine disinfectants after removing the body a woman who died of Ebola virus in the Aberdeen district of Freetown, Sierra Leone, October 14, 2014.  Credit: Reuters/Josephus Olu-Mammah

reuters.com - by Emma Farge - November 26, 2014

(Reuters) - Sierra Leone appealed to the United States on Wednesday to send military aid to help it battle Ebola as it falls behind its West African neighbors Guinea and Liberia in the fight against the virus.

The worst recorded Ebola outbreak has killed at least 5,689 people, the World Health Organization said on Wednesday, as the virus has overwhelmed African countries with weak infrastructure and healthcare systemS.

(READ COMPLETE ARTICLE)

 

Country / Region Tags: 
General Topic Tags: 
Problem, Solution, SitRep, or ?: 

The Race for an Ebola Vaccine

Description of efforts by the big drug companies to develop an Ebloa vaccine
THE NEW YORKER    By Vauhine Vara                        Nov. 25, 2014

"...why this race to create an Ebola vaccine among Merck, GlaxoSmithKline, and Johnson & Johnson—three of the world’s biggest drug manufacturers? For years, pharmaceutical companies didn’t invest much in vaccines, partly because they were so costly and complicated to produce: they’re often made out of live bacteria, which are notoriously difficult to work with. But, over the past several years, companies have realized that the difficulties of making vaccines could be an asset, because they can make it more difficult for generic-drug companies to create copycat versions than for prescription drugs. The vaccine market has also been growing more quickly than the prescription-drug market. The World Health Organization estimates, based on various sources, that global vaccine sales rose from five billion dollars in 2000 to twenty-four billion dollars last year...."

Read complete article
http://www.newyorker.com/business/currency/race-ebola-vaccine

General Topic Tags: 
Problem, Solution, SitRep, or ?: 

U.S. Buys Up Ebola Gear, Leaving Little for Africa

Manufacturers Strain to Meet Demand Amid Rising Anxiety

WALL STREET JOURNAL                                                                                                       Nov. 25, 2014
 By Drew Hinshaw in Accra, Ghana, and Jacob Bunge in Chicago

Protective suits were running low in Sierra Leone this month, when a Christian charity decided to ship some over. The charity turned to American medical-wear suppliers, which came back with bad news: The suits needed to treat Ebola are running low in America, too.

A worker wearing Personal Protective Equipment has his name written on his suit before leaving an Ebola treatment center in Guinea last week. Agence France-Presse/Getty Images

“There’s been some sleepless nights,” said Jennifer Mounsey, director of corporate engagement for World Vision, the Christian humanitarian group based in Monrovia, Calif. “We’re all sweating bullets.”

Problem, Solution, SitRep, or ?: 

Who Will Pay Ebola Patients' Medical Bills in the U.S.?

THE NATIONAL JOURNAL   By Maria Koren           Nov. 24, 2014

...Nine people have been treated for the virus in the U.S. since August. Seven recovered. The National Institutes of Health Clinical Center, which treated one of them, estimates treatment for patients diagnosed with Ebola costs $50,000 a day. Officials at the University of Nebraska Medical Center, which cared for two patients, put the daily cost at $30,000, and the totalat $1.16 million for a single patient. Most patients have been hospitalized for more than two weeks.

The U.S. has shown it can beat Ebola. But who will pay for the expensive care it takes to do it?

It's a tough question, and one that the people holding the bills seem reluctant to answer. Hospitals that have treated patients in Georgia, Nebraska, New York, and Texas did not respond to requests for comment, nor did the governors' offices of these states. NIH was forthcothcoming about cost of care, but the feds pick up the tab for treatment there.

Read complete story

Country / Region Tags: 
General Topic Tags: 
Problem, Solution, SitRep, or ?: 

US Looking Past Ebola to Prepare for Next Outbreak

ASSOCIATED PRESS                                   Nov. 23, 2014
By Lauran Neergarrd Medical Writer

The next Ebola or the next SARS. Maybe even the next HIV. Even before the Ebola epidemic in West Africa is brought under control, public health officials are girding for the next health disaster.

"It's really urgent that we address the weak links and blind spots around the world," Dr. Tom Frieden, director of the Centers for Disease Control and Prevention, told The Associated Press. "Ebola is a powerful reminder that a health threat anywhere can affect us."

Ebola sprang from one of those blind spots, in an area that lacks the health systems needed to detect an outbreak before it becomes a crisis. Now the Obama administration has requested $600 million for the CDC to implement what it calls the Global Health Security Agenda, working with an international coalition to shore up disease detection in high-risk countries and guard against the next contagion....

Read complete story

http://abcnews.go.com/Health/wireStory/us-past-ebola-prepare-outbreak-27114560

Country / Region Tags: 
General Topic Tags: 
Problem, Solution, SitRep, or ?: 

Ebola: Failures of Imagination

psandman.com - October 24th, 2014 -  Jody Lanard and Peter M. Sandman

The alleged U.S. over-reaction to the first three domestic Ebola cases in the United States – what Maryn McKenna calls Ebolanoia – is matched only by the world’s true under-reaction to the risks posed by Ebola in Liberia, Sierra Leone, and Guinea. We are not referring to the current humanitarian catastrophe there, although the world has long been under-reacting to that.

(VIEW COMPLETE ARTICLE)

Country / Region Tags: 
Problem, Solution, SitRep, or ?: 

Probing Ebola's Deadly Inflammatory Effect

      

New research suggests that Ebola's deadly inflammatory effects may be caused by the result of protein shedding by infected cells. (Victor Volchkov / PLOS Pathogens)

CLICK HERE - RESEARCH - PLOS Pathogens - Shed GP of Ebola Virus Triggers Immune Activation and Increased Vascular Permeability

latimes.com - by Monte Morin - November 20, 2014

New research suggests that the massive and destructive inflammation that characterizes Ebola virus disease may be caused by the release of foreign proteins from infected cells.

Although Ebola is infamous for causing bleeding in some of its victims, doctors say the vast majority of deaths are the result of organ failure and shock brought on by the uncontrolled release of cytokines, compounds that cells use to communicate with one another and control immune response. . .

. . . In a paper published Thursday in Plos Pathogens, researchers at the Claude Bernard University of Lyon, in France, argued that glycoprotein shedding by infected cells may explain the immune system's damaging response.

Country / Region Tags: 
General Topic Tags: 
Problem, Solution, SitRep, or ?: 

Officials Revise Goals on Containing Ebola After Signs of Wider Exposure in Mali

NEW YORK TIMES                                     Nov. 21, 2014
By and

The leaders of the United Nations and the World Health Organization expressed renewed alarm on Friday about Ebola’s tenacity in Africa and, in particular, its potential to ravage a fourth country, Mali, where they said hundreds of people had been exposed to an infected cleric who died last month.

Country / Region Tags: 
Problem, Solution, SitRep, or ?: 

Pages

howdy folks
Page loaded in 1.040 seconds.